Koray Tascilar

Department of Medicine 3 – Rheumatology and Immunology

ABATACEPT DELAYS THE DEVELOPMENT OF RA-CLINICAL RESULTS AFTER 18 MONTHS FROM THE RANDOMIZED, PLACEBO-CONTROLLED ARIAA STUDY IN RA-AT RISK PATIENTS (2022) Rech J, Kleyer A, Ostergaard M, Hagen M, Valor L, Tascilar K, Krönke G, et al. Conference contribution THE FMF&AID SURVEY - A PATIENT ORGANIZATION DRIVEN SURVEY FOR AUTOINFLAMMATORY DISEASES (2022) Rech J, Tascilar K, Tufan A, Gattorno M, Kuemmerle-Deschner JB, Ozen S, Krickau T, et al. Conference contribution CHARACTERIZATION OF RELAPSES IN PATIENTS WITH GIANT CELL ARTERITIS (GCA) PATIENTS- DATA FROM THE REAL-LIFE TREATMENT AND SAFETY (REATS)-GCA COHORT (2022) Schönau V, Corte G, Ott S, Tascilar K, Hartmann F, Manger B, Hellmich B, et al. Conference contribution PATIENT SELF-SAMPLING IN RHEUMATOID ARTHRITIS: RESULTS FROM A RANDOMIZED CONTROLLED TRIAL (2022) Knitza J, Tascilar K, Vuillerme N, Vogt E, Matusewicz P, Corte G, Schuster L, et al. Conference contribution LONG-TERM HUMORAL RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASE (2022) Tascilar K, Simon D, Kleyer A, Fagni F, Krönke G, Meder C, Dietrich P, et al. Conference contribution SUBJECTIVE ASSESSMENT OF PHYSICAL FUNCTION DOES NOT SUFFICIENTLY EXPLAIN VARIANCE OF MEASURED HAND FUNCTION AND GRIP STRENGTH IN ARTHRITIS PATIENTS AND NON-ARTHRITIS CONTROLS (2022) Liphardt AM, Tascilar K, Coppers B, Manger E, Liehr S, Bieniek LM, Bayat S, et al. Conference contribution BASELINE CLINICAL DISEASE ACTIVITY IS NOT CRITICAL FOR PREDICTING REMISSION OF ADULTS ONSET STILL'S DISEASE (2022) Groetsch J, Tascilar K, Schett G, Foell D, Rech J Conference contribution A MINIMAL-INVASIVE METHOD TO RETRIEVE AND IDENTIFY ENTHESEAL TISSUE FROM PSORIATIC ARTHRITIS PATIENTS (2022) Raimondo MG, Pachowsky M, Xu C, Rauber S, Tascilar K, Labinsky H, Soare A, et al. Conference contribution BARICITINIB LEADS TO RAPID AND PERSISTENT RESOLUTION OF SYNOVITIS AS MEASURED BY HAND MRI IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA) FAILING CS/BDMARD THERAPY (2022) Kemenes S, Bayat S, Simon D, Krönke G, Bohr D, Valor L, Hartmann F, et al. Conference contribution SIMILAR EFFICACY AND DRUG SURVIVAL RATES OF BARICITINIB MONOTHERAPY AND BARICITINIB/METHOTREXATE COMBINATION THERAPY IN REAL-LIFE TREATMENT OF RHEUMATOID ARTHRITIS - RESULTS FROM A PROSPECTIVE COHORT OF BARICITINIB-TREATED PATIENTS (2022) Bayat S, Tascilar K, Bohr D, Simon D, Kronke G, Hartmann F, Knitza J, et al. Conference contribution, Abstract of a poster